There are clinical trials and there are anecdotal reports, but they are not substantial
retatrutide in Phase III Metabolic focus: Obesity, overweight, type 2 diabetes, sleep apnea, osteoarthritis, MASLD/MASH and cardiovascular/renal outcomes Eli Lillys obesity portfolio includes Zepbound, the newly approved oral GLP-1 drug Foundayo and the Phase III candidate retatrutide
Oral administration of Dihexa achieves 4060% bioavailability with slower absorption kinetics compared to subcutaneous injection, potentially reducing the need for daily dosing due to sustained plasma concentrations
This effect helps control blood sugar levels and prolong feelings of fullness after meals
Side effects of taking Melanotan II nasally include nausea, dizziness, darkening of moles, serious allergic reaction such as anaphylaxis, facial flushing, changes in appetite, and sexual side effects like increased erections due to the hormone used
Heavy coffee consumption and plasma homocysteine: a randomized controlled trial in healthy volunteers